Kodu・Aktsiate loetelu・Innate Pharma SA

I
Innate Pharma SA

Suletud

1.644 2.49

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.634

Max

1.6600000000000001

Põhinäitajad
By Trading Economics
Sissetulek	-28M
Müük	-2.1M
Aktsiakasum	-0.12
Kasumimarginaal	1,342.644
Töötajad	164
EBITDA	-31M

Dividendid
By Acuity
Järgmine tulemuste avaldamine	16. sept 2026

Turustatistika
By TradingEconomics
Turukapital	152M
Eelmine avamishind	-0.85
Eelmine sulgemishind	1.644

Innate Pharma SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. juuli 2026, 23:51 UTC

Macro News

Correlated Moves

Bitcoin is higher as the Trump administration advances plans for a Strategic Bitcoin Reserve, with a federal purchase expected by Q4 2026.

4. juuli 2026, 23:41 UTC

Canada's Balance of Trade data set for July 7, 2026, forecasts a C$2.4 billion surplus amid cautious market optimism despite geopolitical tensions and U.S.-Canada trade concerns.

4. juuli 2026, 23:41 UTC

Brazil's July Inflation Rate Release Sparks Caution Amid Mixed Economic Signals and Global Monetary Policy Shifts

4. juuli 2026, 23:41 UTC

Brazil's June 2026 Inflation Rate Release Sparks Cautious Optimism Amid Easing Pressures and Global Economic Influences

4. juuli 2026, 23:41 UTC

Mexico's June 2026 Inflation Rate Release on July 9 Expected to Influence Market Sentiment Amid Global Economic Trends.

4. juuli 2026, 23:41 UTC

U.S. Exports Data Release on July 7, 2026, Expected to Reflect Resilience Amid Geopolitical Tensions and Market Optimism Following Record Highs

4. juuli 2026, 23:41 UTC

Mexico's Inflation Rate MoM Release on July 9 Expected to Reflect Global Economic Pressures Amid U.S. Monetary Policy Concerns.

4. juuli 2026, 23:41 UTC

U.S. Imports Data Release on July 7, 2026: Market Anticipates Impact of Tariffs and Global Trade Dynamics Amid Cautious Optimism for Economic Stabilization.

4. juuli 2026, 23:41 UTC

U.S. Trade Deficit Expected at $78.8 Billion Amid Weak Job Growth and Easing Geopolitical Tensions

4. juuli 2026, 23:32 UTC

Cryptocurrency Market Gains Amid Weak U.S. Job Data and Cautious Fed Outlook

4. juuli 2026, 23:32 UTC

Bitcoin and Ethereum rise amid positive market sentiment following disappointing U.S. jobs data and easing geopolitical tensions, while investors anticipate key economic releases next week.

4. juuli 2026, 23:32 UTC

U.S. job growth disappoints, shifting Fed rate hike expectations, while Eurozone PMI stabilizes and car registrations surge in Germany.

4. juuli 2026, 23:32 UTC

Cryptocurrency market shows recovery as Bitcoin and Ethereum post gains, while U.S. job growth disappoints, reducing Fed rate hike expectations ahead of July FOMC meeting.

4. juuli 2026, 23:21 UTC

Macro News

Correlated Moves

Ethereum is advancing today, buoyed by Federal Reserve Chair Kevin Warsh's remarks on easing inflation risks and strong market interest ahead of Pepeto's presale.

4. juuli 2026, 23:11 UTC

Correlated Moves

The Russell 2000 Index is trading lower in after-market hours, reflecting a decline since Friday's close amid limited momentum and macroeconomic influences.

4. juuli 2026, 23:11 UTC

Correlated Moves

After-market trading for the Dow Jones Index shows a decline, reflecting a cumulative drop since Friday's close amid shared macroeconomic factors with the S&P 500.

4. juuli 2026, 23:01 UTC

The FTSE 100 Index is lower in after-hours trading, reversing earlier gains. It remains above its 20-day moving average and near its one-month range.

4. juuli 2026, 23:01 UTC

Correlated Moves

Cardano is rising, supported by Ethereum's gains and positive market sentiment. The asset remains above its 20-day moving average, with strong performance over four sessions.

4. juuli 2026, 23:01 UTC

Macro News

The S&P 500 Index is lower in after-market hours amid rising memory chip costs and escalating geopolitical tensions following a Ukrainian drone attack.

4. juuli 2026, 23:01 UTC

The Nasdaq 100 Index is lower in after-hours trading, continuing a decline since Friday's close without any specific news to explain the movement.

4. juuli 2026, 22:51 UTC

Brazil's Retail Sales MoM data set for July 8, 2026, shows cautious optimism as analysts predict recovery from April’s -1.5% decline amid positive economic sentiment linked to World Cup events.

4. juuli 2026, 22:51 UTC

The DAX 30 Index is trading lower in after-market hours, reflecting a decline since Friday's close and contrasting with recent upward momentum.

4. juuli 2026, 22:41 UTC

Cautious Optimism Grows Ahead of MBA Mortgage Rate Release Amid Easing Inflation and Weaker Jobs Data

4. juuli 2026, 22:31 UTC

Japan's Current Account Data Release on July 7, 2026, Forecasts JPY 4.12 Trillion Surplus Amid Market Volatility and Global Economic Concerns.

4. juuli 2026, 22:31 UTC

Brazil's Central Bank to Discuss SELIC Rate Amid Mixed Economic Signals and Global Influences on July 6, 2026.

4. juuli 2026, 22:11 UTC

UK Housing Market Faces Continued Downward Pressure as RICS House Price Balance Forecasts -0.32% Amid Economic Challenges

4. juuli 2026, 21:51 UTC

Japan's Household Spending YoY data set for July 6, 2026, expected to decline amid cautious market sentiment and global economic pressures.

4. juuli 2026, 21:51 UTC

Japan's Household Spending Expected to Rise 1.4% in May Amid Mixed Economic Sentiment and Positive Service Sector Growth

4. juuli 2026, 21:01 UTC

Macro News

Brent crude prices are lower in after-market hours following a Ukrainian drone attack on an oil terminal in St. Petersburg, intensifying the fuel crisis in Russia.

4. juuli 2026, 20:21 UTC

ECB President Lagarde's upcoming speech sparks cautious market sentiment on Eurozone interest rate hikes amid easing inflation pressures.

Võrdlus sarnastega

Hinnamuutus

Innate Pharma SA Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Innate Pharma SA aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Innate Pharma SA

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.